The note says investors can buy in the Rs 653-667 band and add on declines to Rs 597-607, projecting 14% revenue CAGR, 220bps margin improvement and 25% PAT CAGR over FY26-29E, supported by the company's position as the world's only scaled non-Chinese pyridine producer, a Rs 1,700 crore completed capex cycle, CDMO ramp-up and management's FY27 EBITDA guidance of Rs 750-800 crore.
Read this note →Jubilant Ingrevia Limited
NSE JUBLINGREA BSE 543271 INE0BY001018
0 filings · 0 analysed
587.65
+4.61%
over 5 days
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities Limited | 27 Sep 2026, 14:15 | long | 656.10 | 722.00 | 572.40 | -100% | open by 2027-09-27 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief